Biolex Therapeutics, Inc. · Pittsboro, NC United States
| 158 Credle St. | Phone: 919-542-9901 |
| Pittsboro, NC | Fax: 919-542-9910 |
| 27312 | |
| United States | 
Map This Company |
Biolex Therapeutics, Inc. Rankings
Company Description
More than a catalyst for change, Biolex Therapeutics (formerly Biolex, Inc.) wants to be a catalyst for transmogrification. Biolex uses its LEX System and "Plantibodies" technologies for harvesting proteins from Lemna, an aquatic plant, and genetically transforming them into monoclonal antibodies for use in treating human diseases such as hepatitis C. Its lead drug candidate, Locteron, when combined with ribavarin, greatly reduces the viral load of the disease while causing fewer side effects. Its BLX-155 is used to dissolve blood clots; BLX-301 is designated for treating non-Hodgkin's B-cell lymphoma. Chairman Chris Hegal owns just under 25% of the company. Biolex has withdrawn its IPO filing.
Biolex Therapeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | PrivateHeadquarters |
|---|---|
| Fiscal Year-End | December |
| Employees | 46 |
Executives
46 executives listed for Biolex Therapeutics, Inc.'s Pittsboro, NC location.
| Chairman | Kurt Graves | |
|---|---|---|
| President, CEO, and Director | Jan Turek | |
| SVP Research and Development and COO | David Spencer |